Long Term Pegylated Interferon Alfa-2b Therapy In Stage III Melanoma Demonstrated Significant And Sustained Impact On Relapse-Free Survival
Schering-Plough (NYSE: SGP) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sustained impact on relapse-free survival (RFS), according to results of a randomized phase III trial published in The Lancet.
This post is an original post by ScienceDaily: Skin Care News
Posted: July 12th, 2008 under skin health.
Comments: none
Write a comment